BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 12745013)

  • 1. Biodistribution of [111In-DTPA-D-Phe1]-octreotide in dogs: uptake in the stomach and intestines but not in the spleen points towards interspecies differences.
    Robben J; Claude Reubi J; Pollak Y; Voorhout G
    Nucl Med Biol; 2003 Apr; 30(3):225-32. PubMed ID: 12745013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crucial role for somatostatin receptor subtype 2 in determining the uptake of [111In-DTPA-D-Phe1]octreotide in somatostatin receptor-positive organs.
    Hofland LJ; Lamberts SW; van Hagen PM; Reubi JC; Schaeffer J; Waaijers M; van Koetsveld PM; Srinivasan A; Krenning EP; Breeman WA
    J Nucl Med; 2003 Aug; 44(8):1315-21. PubMed ID: 12902423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distribution and elimination characteristics of 111In-DTPA-D-phe1-octreotide and 111In-DTPA-L-phe1-octreotide in rats.
    Laznickova A; Laznicek M; Trejtnar F; Melicharova L; Suzuki KH; Akizawa H; Arano Y; Yokoyama A
    Eur J Drug Metab Pharmacokinet; 2002; 27(1):37-43. PubMed ID: 11996325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal metabolism of 111In-DTPA-D-Phe1-octreotide in vivo.
    Akizawa H; Arano Y; Uezono T; Ono M; Fujioka Y; Uehara T; Yokoyama A; Akaji K; Kiso Y; Koizumi M; Saji H
    Bioconjug Chem; 1998; 9(6):662-70. PubMed ID: 9815158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nuclear localization of 111In after intravenous injection of [111In-DTPA-D-Phe1]-octreotide in patients with neuroendocrine tumors.
    Janson ET; Westlin JE; Ohrvall U; Oberg K; Lukinius A
    J Nucl Med; 2000 Sep; 41(9):1514-8. PubMed ID: 10994731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. D-lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake.
    Bernard BF; Krenning EP; Breeman WA; Rolleman EJ; Bakker WH; Visser TJ; Mäcke H; de Jong M
    J Nucl Med; 1997 Dec; 38(12):1929-33. PubMed ID: 9430472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhomogeneous localization of radioactivity in the human kidney after injection of [(111)In-DTPA]octreotide.
    De Jong M; Valkema R; Van Gameren A; Van Boven H; Bex A; Van De Weyer EP; Burggraaf JD; Körner M; Reubi JC; Krenning EP
    J Nucl Med; 2004 Jul; 45(7):1168-71. PubMed ID: 15235063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biodistribution of 111in-DTPA-D-Phe1-octreotide in tumor-bearing nude mice: influence of amount injected and route of administration.
    Bernhardt P; Kölby L; Johanson V; Nilsson O; Ahlman H; Forssell-Aronsson E
    Nucl Med Biol; 2003 Apr; 30(3):253-60. PubMed ID: 12745016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide.
    Krenning EP; Bakker WH; Kooij PP; Breeman WA; Oei HY; de Jong M; Reubi JC; Visser TJ; Bruns C; Kwekkeboom DJ
    J Nucl Med; 1992 May; 33(5):652-8. PubMed ID: 1349039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Megalin is essential for renal proximal tubule reabsorption of (111)In-DTPA-octreotide.
    de Jong M; Barone R; Krenning E; Bernard B; Melis M; Visser T; Gekle M; Willnow TE; Walrand S; Jamar F; Pauwels S
    J Nucl Med; 2005 Oct; 46(10):1696-700. PubMed ID: 16204720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?
    Storch D; Béhé M; Walter MA; Chen J; Powell P; Mikolajczak R; Mäcke HR
    J Nucl Med; 2005 Sep; 46(9):1561-9. PubMed ID: 16157541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide.
    Barone R; Walrand S; Konijnenberg M; Valkema R; Kvols LK; Krenning EP; Pauwels S; Jamar F
    Nucl Med Commun; 2008 Mar; 29(3):283-90. PubMed ID: 18349800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biokinetics of 111In-DTPA-D-Phe(1)-octreotide in nude mice transplanted with a human carcinoid tumor.
    Bernhardt P; Kölby L; Johanson V; Benjegård SA; Nilsson O; Ahlman H; Forssell-Aronsson E
    Nucl Med Biol; 2001 Jan; 28(1):67-73. PubMed ID: 11182566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gluc-Lys([18F]FP)-TOCA PET in patients with SSTR-positive tumors: biodistribution and diagnostic evaluation compared with [111In]DTPA-octreotide.
    Meisetschläger G; Poethko T; Stahl A; Wolf I; Scheidhauer K; Schottelius M; Herz M; Wester HJ; Schwaiger M
    J Nucl Med; 2006 Apr; 47(4):566-73. PubMed ID: 16595488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [111In-DTPA-D-Phe]-octreotide scintigraphy in functioning and non-functioning pituitary adenomas.
    Boni G; Ferdeghini M; Bellina CR; Matteucci F; Castro Lopez E; Parenti G; Canapicchi R; Bianchi R
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):90-3. PubMed ID: 9002759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biodistribution data from 100 patients i.v. injected with 111In-DTPA-D-Phe1-octreotide.
    Forssell-Aronsson E; Bernhardt P; Nilsson O; Tisell LE; Wängberg B; Ahlman H
    Acta Oncol; 2004; 43(5):436-42. PubMed ID: 15360047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 111In-DTPA-D-Phe-1-octreotide scintigraphy of small cell lung cancer.
    Bombardieri E; Chiti A; Crippa F; Seregni E; Cataldo I; Maffioli L; Soresi E
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):104-7. PubMed ID: 9002763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physiological Uptake in the Pancreatic Head on Somatostatin Receptor Scintigraphy Using [111In-DTPA]Octreotide: Incidence and Mechanism.
    Brabander T; Teunissen J; Kwekkeboom D
    Clin Nucl Med; 2017 Jan; 42(1):15-19. PubMed ID: 27775943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant thyrotropin-induced orbital uptake of [111In-diethylenetriamine-pentacetic acid-D-Phe1]octreotide in a patient with inactive Graves' ophthalmopathy.
    Savastano S; Pivonello R; Acampa W; Salvatore M; Lombardi G; Colao A; Fenzi G
    J Clin Endocrinol Metab; 2005 Apr; 90(4):2440-4. PubMed ID: 15687327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo studies of three radiolabelled somatostatin analogues: 123I-octreotide (OCT), 123I-Tyr-3-OCT and 111In-DTPA-D-Phe-1-OCT.
    Virgolini I; Angelberger P; Li S; Yang Q; Kurtaran A; Raderer M; Neuhold N; Kaserer K; Leimer M; Peck-Radosavljevic M; Scheithauer W; Niederle B; Eichler HG; Valent P
    Eur J Nucl Med; 1996 Oct; 23(10):1388-99. PubMed ID: 8781146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.